Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2010 1
2011 1
2012 1
2013 4
2014 4
2015 4
2016 4
2017 12
2018 7
2019 6
2020 3
2021 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Aroldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P. Pizzuti L, et al. Among authors: mentuccia l. J Cell Physiol. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10. J Cell Physiol. 2019. PMID: 30536609
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.
Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F. Vici P, et al. Among authors: mentuccia l. Oncotarget. 2016 Apr 5;7(14):17932-44. doi: 10.18632/oncotarget.7480. Oncotarget. 2016. PMID: 26910921 Free PMC article.
Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study.
Barni S, Livraghi L, Gravina A, Martella F, D'Onofrio L, Morritti M, Michelotti A, Vici P, Mentuccia L, Porcu L, Orditura M, Puglisi F; ESEMPiO Group. Barni S, et al. Among authors: mentuccia l. J Geriatr Oncol. 2019 Nov;10(6):990-993. doi: 10.1016/j.jgo.2019.05.003. Epub 2019 May 13. J Geriatr Oncol. 2019. PMID: 31097340 No abstract available.
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin.
Barba M, Pizzuti L, Sperduti I, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Izzo F, Rinaldi M, Mentuccia L, Vaccaro A, Iezzi L, Grassadonia A, Michelotti A, Landucci E, Perracchio L, Pescarmona E, Di Filippo F, Giordano A, Maugeri-Saccà M, Vici P. Barba M, et al. Among authors: mentuccia l. J Cell Physiol. 2016 May;231(5):986-91. doi: 10.1002/jcp.25213. Epub 2015 Nov 20. J Cell Physiol. 2016. PMID: 26449308
Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control.
La Verde N, Moretti A, Farina G, Dazzani MC, Gamucci T, Borgonovo K, Botta M, Salesi N, Zuradelli M, Pavese I, Barbieri E, Cretella E, Saladino T, Varese P, Traverso ES, Addamo G, Ciccarese M, Rispoli AI, Pellegrino A, Mentuccia L, Girelli S, Piva S, Di Maio M. La Verde N, et al. Among authors: mentuccia l. Future Oncol. 2013 Dec;9(12):1841-8. doi: 10.2217/fon.13.216. Future Oncol. 2013. PMID: 24295414
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, Izzo F, Marchetti L, Tomao S, Marchetti P, Natoli C, Grassadonia A, Gamucci T, Mentuccia L, Magnolfi E, Vaccaro A, Cassano A, Rossi E, Botticelli A, Sini V, Sarobba MG, Fabbri MA, Moscetti L, Astone A, Michelotti A, De Angelis C, Bertolini I, Angelini F, Ciliberto G, Maugeri-Saccà M, Giordano A, Barba M, Vici P. Pizzuti L, et al. Among authors: mentuccia l. Cancer Biol Ther. 2018 Apr 3;19(4):328-334. doi: 10.1080/15384047.2017.1416938. Epub 2018 Feb 16. Cancer Biol Ther. 2018. PMID: 29336662 Free PMC article.
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P. Gamucci T, et al. Among authors: mentuccia l. J Cell Physiol. 2018 Mar;233(3):2313-2323. doi: 10.1002/jcp.26103. Epub 2017 Sep 27. J Cell Physiol. 2018. PMID: 28710865
Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?
Grassadonia A, Vici P, Gamucci T, Moscetti L, Pizzuti L, Mentuccia L, Iezzi L, Scognamiglio MT, Zilli M, Giampietro J, Graziano V, Natoli C, Tinari N. Grassadonia A, et al. Among authors: mentuccia l. Breast. 2017 Oct;35:218-219. doi: 10.1016/j.breast.2017.05.006. Epub 2017 May 17. Breast. 2017. PMID: 28526175 No abstract available.
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Cazzaniga ME, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoldi M, Moretti G, Ficorella C, Gianni L, Michelotti A, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi GV, Artale S, Blasi L, De Laurentiis M, Atzori F, Turletti A, Porpiglia M, Santini D, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Giordano M, Donadio M, Biganzoli L, Del Mastro L, Bisagni G, Livi L, Natoli C, Montemurro F, Riccardi F, Romagnoli E, Marchetti P, Torri V, Pronzato P, Mustacchi G. Cazzaniga ME, et al. Among authors: mentuccia l. Breast Care (Basel). 2020 Feb;15(1):30-37. doi: 10.1159/000495469. Epub 2019 Apr 17. Breast Care (Basel). 2020. PMID: 32231495 Free PMC article.
40 results